Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Favipiravir - FUJIFILM Toyama Chemical

Next Previous
X
Search
Drug Profile

Favipiravir - FUJIFILM Toyama Chemical

Alternative Names: Avigan; Qifenda; REEQONUS; T-705; T-705a

Latest Information Update: 28 May 2023

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Toyama Chemical
  • Developer Appili Therapeutics; BioDefense Therapeutics; Dr Reddys Laboratories; FUJIFILM Holdings Corporation; FujiFilm Pharmaceuticals USA; FUJIFILM Toyama Chemical; Institut national de la sante et de la recherche medicale; MediVector; Toyama Chemical; Zhejiang Hisun Pharmaceutical
  • Class Amides; Antivirals; Fluorinated hydrocarbons; Ketones; Pyrazines; Small molecules
  • Mechanism of Action RNA replicase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed COVID 2019 infections
  • Registered Influenza virus infections
  • Phase III Severe fever with thrombocytopenia syndrome
  • Phase II Ebola virus infections

Most Recent Events

  • 28 May 2023 No recent reports of development identified for clinical-Phase-Unknown development in COVID-2019-infections in Middle East (PO, Tablet)
  • 28 Apr 2023 No recent reports of development identified for clinical-Phase-Unknown development in COVID-2019-infections in Turkey (PO, Tablet)
  • 15 Dec 2022 FUJIFILM Corporation plans to withdraw regulatory application to partially amend manufacturing and marketing approval in Japan due to discontinued development of favipiravir in COVID-2019 infections

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top